- Medical School - University of California, San Francisco (2001-2005)
- Residency - University of Colorado - Children's Hospital Colorado - Pediatric Internship/Residency (2005-2009), Pediatrics
- Fellowship - Children's Hospital of Philadelphia - Pediatric Hema/Onco Fellowship (2009-2012), Pediatric Hematology/oncology
Theodore Laetsch, M.D.
- Norma and Jim Smith Professorship in Clinical Excellence, in Honor of Dr. John Warner
- Eugene P. Frenkel, M.D. Scholar in Clinical Medicine
- Pediatrics - Hematology-Oncology
Theodore W. Laetsch, MD is a faculty member in the Department of Pediatrics at the University of Texas Southwestern Medical Center in Dallas, TX. He also leads the Experimental Therapeutics Program (ETP) in the Gill Center for Cancer and Blood Disorders at Children’s Health in Dallas, TX. Dr. Laetsch received a BS in Agricultural and Biosystems Engineering from the University of Arizona and then a MD from the University of California, San Francisco. Dr. Laetsch completed his residency at the University of Colorado/Children’s Hospital Colorado, where he also served as chief resident. He completed his fellowship training and an instructorship at the Children's Hospital of Philadelphia (CHOP), where he conducted translational laboratory research focused on mechanisms to restore apoptotic signaling in neuroblastoma in the laboratory of Dr. Michael Hogarty. In 2013, he joined the faculty at UT Southwestern. Dr. Laetsch conducts both clinical and laboratory-based research testing potential novel therapeutics in high-risk pediatric solid tumors with a goal of “bridging the gap” between laboratory research and early phase clinical trials. In the laboratory, he has focused on signaling pathway inhibitors and novel drug delivery mechanisms in sarcomas, and the use of beta-lapachone in ATRTs. As the leader of the ETP program, Dr. Laetsch serves as the PI of several phase 1 and phase 2 studies of new agents for children with relapsed or refractory cancer and serves as the institutional TACL PI. Dr. Laetsch has a strong interest in the use of tumor molecular profiling to guide therapy. In addition to these research activities, Dr. Laetsch continues to see children with cancer in the clinic at Children’s Medical Center.
In 2018, Dr. Laetsch received UT Southwestern's Rising Star Award.
- Children's Oncology Group (2009)
- American Society of Pediatric Hematology/Oncology (2009)
- American Society of Clinical Oncology (2010)
- American Association of Cancer Research (2010)
- Alpha Omega Alpha Member 2004
- Gold Headed Cane Society Member 2005
- Joseph W. St. Geme, Jr., M.D. Award for Outstanding Research as a Resident 2008
- NICHD Child Health Research Career Development Award (K12) 2012
Clinical Pharmacology of Tisagenlecleucel in B-Cell Acute Lymphoblastic Leukemia.
Mueller KT, Waldron ER, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August K, Hamilton J, Awasthi R, Stein AM, Sickert D, Chakraborty A, Levine BL, June CH, Tomassian L, Shah S, Leung M, Taran T, Wood PA, Maude SL Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Sep
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.
Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2018 Dec
Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells.
Stein AM, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Levine BL, Tomassian L, Shah S, Leung M, Huang PH, Awasthi R, Mueller KT, Wood PA, June CH, CPT: pharmacometrics & systems pharmacology 2019 Mar
The Use of Neoadjuvant Larotrectinib in the Management of Children With Locally Advanced TRK Fusion Sarcomas.
DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM, Nagasubramanian R, Anderson ME, Davis JL, Qamoos HE, Reynolds ME, Cruickshank S, Cox MC, Hawkins DS, Mascarenhas L, Pappo AS Cancer 2018 Sep
Larotrectinib for the treatment of TRK fusion solid tumors.
Laetsch TW, Hawkins DS Expert review of anticancer therapy 2018 Oct 1-10
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM The New England journal of medicine 2018 02 378 8 731-739
Comprehensive Analysis of Hypermutation in Human Cancer.
Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, Zahurancik WJ, Suo Z, Lipman T, Wimmer K, Kratz CP, Bowers DC, Laetsch TW, Dunn GP, Johanns TM, Grimmer MR, Smirnov IV, Larouche V, Samuel D, Bronsema A, Osborn M, Stearns D, Raman P, Cole KA, Storm PB, Yalon M, Opocher E, Mason G, Thomas GA, Sabel M, George B, Ziegler DS, Lindhorst S, Issai VM, Constantini S, Toledano H, Elhasid R, Farah R, Dvir R, Dirks P, Huang A, Galati MA, Chung J, Ramaswamy V, Irwin MS, Aronson M, Durno C, Taylor MD, Rechavi G, Maris JM, Bouffet E, Hawkins C, Costello JF, Meyn MS, Pursell ZF, Malkin D, Tabori U, Shlien A Cell 2017 Oct
Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.
Allen CE, Laetsch TW, Mody R, Irwin MS, Lim MS, Adamson PC, Seibel NL, Parsons DW, Cho YJ, Janeway K Journal of the National Cancer Institute 2017 May 109 5
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert CM, Nagasubramanian R, Davis JL, Rudzinski E, Feraco AM, Tuch BB, Ebata KT, Reynolds M, Smith S, Cruickshank S, Cox MC, Pappo AS, Hawkins DS The Lancet. Oncology 2018 Mar
A case of advanced infantile myofibromatosis harboring a novel MYH10-RET fusion.
Rosenzweig M, Ali SM, Wong V, Schrock AB, Laetsch TW, Heilmann A, Morley S, Chudnovsky Y, Erlich RL, Wang K, Stephens PJ, Ross JS, Miller VA, Oesterheld J Pediatric blood & cancer 2016 Dec
Targeting NTRK fusions for the treatment of congenital mesoblastic nephroma.
Laetsch TW, Nagasubramanian R, Casanova M Pediatric blood & cancer 2017 Apr
False-positive results following lentiviral-based tisagenlecleucel therapy with select HIV-1 NAT methods.
Laetsch TW, Maude SL, Milone MC, Davis KL, Krueger J, Cardenas AM, Eldjerou LK, Keir CH, Wood PA, Grupp SA Blood 2018 Apr
Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue.
Shuen AY, Lanni S, Panigrahi GB, Edwards M, Yu L, Campbell BB, Mandel A, Zhang C, Zhukova N, Alharbi M, Bernstein M, Bowers DC, Carroll S, Cole KA, Constantini S, Crooks B, Dvir R, Farah R, Hijiya N, George B, Laetsch TW, Larouche V, Lindhorst S, Luiten RC, Magimairajan V, Mason G, Mason W, Mordechai O, Mushtaq N, Nicholas G, Oren M, Palma L, Pedroza LA, Ramdas J, Samuel D, Wolfe Schneider K, Seeley A, Semotiuk K, Shamvil A, Sumerauer D, Toledano H, Tomboc P, Wierman M, Van Damme A, Lee YY, Zapotocky M, Bouffet E, Durno C, Aronson M, Gallinger S, Foulkes WD, Malkin D, Tabori U, Pearson CE Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Feb 37 6 461-470
Integrative Bayesian Analysis Identifies Rhabdomyosarcoma Disease Genes.
Xu L, Zheng Y, Liu J, Rakheja D, Singleterry S, Laetsch TW, Shern JF, Khan J, Triche TJ, Hawkins DS, Amatruda JF, Skapek SX Cell reports 2018 Jul 24 1 238-251
Undifferentiated sarcomas in children harbor clinically-relevant oncogenic fusions and gene copy-number alterations: A report from the Children's Oncology Group.
Laetsch TW, Roy A, Xu L, Black JO, Coffin CM, Chi YY, Tian J, Spunt SL, Hawkins DS, Bridge JA, Parsons DW, Skapek SX Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Apr
Redefining treatment failure for pediatric acute leukemia in the era of minimal residual disease testing.
Huynh V, Laetsch TW, Schore RJ, Gaynon P, O'Brien MM Pediatric hematology and oncology 2017 Nov 1-14
Pediatric oncology enters an era of precision medicine.
Seibel NL, Janeway K, Allen CE, Chi SN, Cho YJ, Glade Bender JL, Kim A, Laetsch TW, Irwin MS, Takebe N, Tricoli JV, Parsons DW Current problems in cancer 2017 Feb
Pediatric Sarcomas Are Targetable by MR-Guided High Intensity Focused Ultrasound (MR-HIFU): Anatomical Distribution and Radiological Characteristics.
Shim J, Staruch RM, Koral K, Xie XJ, Chopra R, Laetsch TW Pediatric blood & cancer 2016 May
Multiple components of the spliceosome regulate Mcl1 activity in neuroblastoma.
Laetsch TW, Liu X, Vu A, Sliozberg M, Vido M, Elci OU, Goldsmith KC, Hogarty MD Cell death & disease 2014 5 e1072
TRK Fusion Cancers in Children: A Clinical Review and Recommendations for Screening.
Albert CM, Davis JL, Federman N, Casanova M, Laetsch TW Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Feb 37 6 513-524
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, Heym K, Laetsch TW, Widener M, Rheingold SR, Oesterheld J, Hijiya N, Sulis ML, Huynh V, Place AE, Bittencourt H, Hutchinson R, Messinger Y, Chang B, Matloub Y, Ziegler DS, Gardner R, Cooper T, Ceppi F, Hermiston M, Dalla-Pozza L, Schultz KR, Gaynon P, Wayne AS, Whitlock JA Leukemia 2018 Mar
EGF Receptor and mTORC1 are novel therapeutic targets in nonseminomatous germ cell tumors.
Chen KS, Fustino NJ, Shukla AA, Stroup EK, Budhipramono A, Ateek C, Stuart SH, Yamaguchi K, Kapur P, Frazier AL, Lum L, Looijenga LHJ, Laetsch TW, Rakheja D, Amatruda JF Molecular cancer therapeutics 2018 Feb
Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors.
Davis JL, Lockwood CM, Stohr B, Boecking C, Al-Ibraheemi A, DuBois SG, Vargas SO, Black JO, Cox MC, Luquette M, Turpin B, Szabo S, Laetsch TW, Albert CM, Parham DM, Hawkins DS, Rudzinski ER The American journal of surgical pathology 2018 Dec
Longer heating duration increases localized doxorubicin deposition and therapeutic index in Vx2 tumors using MR-HIFU mild hyperthermia and thermosensitive liposomal doxorubicin.
Bing C, Patel P, Staruch RM, Shaikh S, Nofiele J, Wodzak Staruch M, Szczepanski D, Williams NS, Laetsch T, Chopra R International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2018 Dec 1-8
Pan-Trk Immunohistochemistry Identifies NTRK rearrangements in Pediatric Mesenchymal Tumors.
Rudzinski ER, Lockwood CM, Stohr BA, Vargas SO, Sheridan R, Black JO, Rajaram V, Laetsch TW, Davis JL The American journal of surgical pathology 2018 Apr
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA The New England journal of medicine 2018 02 378 5 439-448
Drift correction for accurate PRF-shift MR thermometry during mild hyperthermia treatments with MR-HIFU.
Bing C, Staruch RM, Tillander M, Köhler MO, Mougenot C, Ylihautala M, Laetsch TW, Chopra R International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2016 May 1-15
Polyamine antagonist therapies inhibit neuroblastoma initiation and progression.
Evageliou NF, Haber M, Vu A, Laetsch TW, Murray J, Gamble LD, Cheng NC, Liu K, Reese M, Corrigan KA, Ziegler DS, Webber HT, Hayes CS, Pawel BR, Marshall GM, Zhao H, Gilmour SK, Norris MD, Hogarty MD Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Mar
Potential pitfalls of mass spectrometry to uncover mutations in childhood soft tissue sarcoma: A report from the Children's Oncology Group.
Xu L, Wilson RA, Laetsch TW, Oliver D, Spunt SL, Hawkins DS, Skapek SX Scientific reports 2016 6 33429
Temperature-dependent MR signals in cortical bone: Potential for monitoring temperature changes during high-intensity focused ultrasound treatment in bone.
Ramsay E, Mougenot C, Kazem M, Laetsch TW, Chopra R Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 2014 Oct
- Clinical Pharmacology of Tisagenlecleucel in B-Cell Acute Lymphoblastic Leukemia.
- Tumor Genomic Profiling
- Novel Therapeutics for Childhood Cancer